new glp 1 drugs coming project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these at scale. Our GLP-1 Drugs and Type 1

References Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical Programme, 16 September 2025, Novo Nordisk, DAscanio AM, Mullally JA, Frishman WH

1e were suggested for slow thermodynamic thiol-disulfide equilibrations between different glutaredoxins, GSH, and the metal-binding domains of the proteins HMA4 and Atox1 60

Smooth integration with your branding and logistics is essential

3 Advantages of L-Ergothioneine Over Other Antioxidants The antioxidant activity of EGT has many advantages over other antioxidants such as GSH and ascorbic acid (Nielsen et al., 2015